VXRT vs. DBVT, MOLN, CRDL, VIGL, OMGA, SCLX, LIFE, CRDF, BCAB, and SGMO
Should you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include DBV Technologies (DBVT), Molecular Partners (MOLN), Cardiol Therapeutics (CRDL), Vigil Neuroscience (VIGL), Omega Therapeutics (OMGA), Scilex (SCLX), aTyr Pharma (LIFE), Cardiff Oncology (CRDF), BioAtla (BCAB), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry.
DBV Technologies (NASDAQ:DBVT) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 18.1% of Vaxart shares are owned by institutional investors. 0.6% of DBV Technologies shares are owned by insiders. Comparatively, 3.0% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
DBV Technologies has higher revenue and earnings than Vaxart. DBV Technologies is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.
DBV Technologies has a net margin of -461.32% compared to DBV Technologies' net margin of -1,117.56%. Vaxart's return on equity of -46.33% beat DBV Technologies' return on equity.
DBV Technologies currently has a consensus price target of $3.33, indicating a potential upside of 397.51%. Vaxart has a consensus price target of $3.00, indicating a potential upside of 310.96%. Given Vaxart's higher probable upside, research analysts plainly believe DBV Technologies is more favorable than Vaxart.
DBV Technologies received 90 more outperform votes than Vaxart when rated by MarketBeat users. However, 65.47% of users gave Vaxart an outperform vote while only 57.25% of users gave DBV Technologies an outperform vote.
DBV Technologies has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.
In the previous week, DBV Technologies had 8 more articles in the media than Vaxart. MarketBeat recorded 11 mentions for DBV Technologies and 3 mentions for Vaxart. Vaxart's average media sentiment score of 0.23 beat DBV Technologies' score of 0.20 indicating that DBV Technologies is being referred to more favorably in the media.
Summary
DBV Technologies beats Vaxart on 12 of the 17 factors compared between the two stocks.
Get Vaxart News Delivered to You Automatically
Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
